$LUMO
Lumos Pharma Inc

2020 Q2 Form 10-Q Financial Statement

#000112623420000114 Filed on August 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $33.00K $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.100M $700.0K
YoY Change 485.71% -91.14%
% of Gross Profit
Research & Development $2.763M $1.881M
YoY Change 46.89% -84.44%
% of Gross Profit
Depreciation & Amortization $200.0K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $6.910M $2.595M
YoY Change 166.28% -87.03%
Operating Profit -$6.877M -$2.595M
YoY Change 165.01% -85.38%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $98.00K $26.00K
YoY Change 276.92% -94.02%
Pretax Income -$6.779M -$2.569M
YoY Change 163.88% -85.16%
Income Tax -$1.426M $0.00
% Of Pretax Income
Net Earnings -$5.353M -$2.569M
YoY Change 108.37% -85.16%
Net Earnings / Revenue -16221.21%
Basic Earnings Per Share -$0.65 -$0.27
Diluted Earnings Per Share -$0.65 -$2.000M
COMMON SHARES
Basic Shares Outstanding 8.293M shares 37.28M shares
Diluted Shares Outstanding 8.293M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $72.70M $105.4M
YoY Change -31.02% -23.12%
Cash & Equivalents $72.70M $105.4M
Short-Term Investments
Other Short-Term Assets $93.10M $4.000M
YoY Change 2227.5% -23.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables $296.0K $458.0K
Total Short-Term Assets $170.7M $110.2M
YoY Change 54.94% -23.2%
LONG-TERM ASSETS
Property, Plant & Equipment $834.0K $3.314M
YoY Change -74.83% -24.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.461M $10.61M
YoY Change -86.23% 134.44%
TOTAL ASSETS
Total Short-Term Assets $170.7M $110.2M
Total Long-Term Assets $1.461M $10.61M
Total Assets $172.2M $120.8M
YoY Change 42.54% -18.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $155.0K $689.0K
YoY Change -77.5% -90.61%
Accrued Expenses $5.944M $7.235M
YoY Change -17.84% -15.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $100.0K
YoY Change -100.0% 0.0%
Total Short-Term Liabilities $42.56M $8.628M
YoY Change 393.29% -46.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $6.100M $13.50M
YoY Change -54.81% 92.86%
Total Long-Term Liabilities $13.17M $13.50M
YoY Change -2.4% 92.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.56M $8.628M
Total Long-Term Liabilities $13.17M $13.50M
Total Liabilities $55.73M $22.12M
YoY Change 151.91% -4.09%
SHAREHOLDERS EQUITY
Retained Earnings -$65.34M -$311.2M
YoY Change -79.0% 13.97%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.450M
YoY Change 3.2%
Treasury Stock Shares 112.1K shares
Shareholders Equity $116.5M -$53.01M
YoY Change
Total Liabilities & Shareholders Equity $172.2M $120.8M
YoY Change 42.54% -18.38%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$5.353M -$2.569M
YoY Change 108.37% -85.16%
Depreciation, Depletion And Amortization $200.0K $0.00
YoY Change -100.0%
Cash From Operating Activities -$13.10M -$2.300M
YoY Change 469.57% -66.67%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -13.10M -2.300M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -13.10M -2.300M
YoY Change 469.57% -66.18%
FREE CASH FLOW
Cash From Operating Activities -$13.10M -$2.300M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$13.10M -$2.300M
YoY Change 469.57% -66.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
215-2630
dei Entity Central Index Key
EntityCentralIndexKey
0001126234
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1111
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35342
dei Entity Registrant Name
EntityRegistrantName
LUMOS PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
42-1491350
dei Entity Address Address Line1
EntityAddressAddressLine1
4200 Marathon Blvd #200
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78756
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
LUMO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8293312 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72697000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4952000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5158000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
82000 USD
CY2020Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
4666000 USD
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0 USD
CY2020Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
296000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
35000 USD
CY2020Q2 nlnk Economic Interest In Priority Review Voucher Held For Sale Current
EconomicInterestInPriorityReviewVoucherHeldForSaleCurrent
87920000 USD
CY2019Q4 nlnk Economic Interest In Priority Review Voucher Held For Sale Current
EconomicInterestInPriorityReviewVoucherHeldForSaleCurrent
0 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
170737000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
5069000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
834000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
84000 USD
CY2020Q2 nlnk Operating Lease Rightof Use Asset Noncurrent
OperatingLeaseRightofUseAssetNoncurrent
627000 USD
CY2019Q4 nlnk Operating Lease Rightof Use Asset Noncurrent
OperatingLeaseRightofUseAssetNoncurrent
373000 USD
CY2020Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
1461000 USD
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
457000 USD
CY2020Q2 us-gaap Assets
Assets
172198000 USD
CY2019Q4 us-gaap Assets
Assets
5526000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
155000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
365000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5944000 USD
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
191000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
709000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
731000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
189000 USD
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
11000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
0 USD
CY2020Q2 nlnk Priority Review Voucher Liability Held For Sale
PriorityReviewVoucherLiabilityHeldForSale
35720000 USD
CY2019Q4 nlnk Priority Review Voucher Liability Held For Sale
PriorityReviewVoucherLiabilityHeldForSale
0 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
42561000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1263000 USD
CY2020Q2 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
6000000 USD
CY2019Q4 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
0 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
88000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
191000 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7084000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 USD
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13172000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
55733000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
1454000 USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
36000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8293312 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8293312 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1177933 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1177933 shares
CY2020Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
83000 USD
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
12000 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
181723000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65341000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59677000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
116465000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-59463000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
172198000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5526000 USD
CY2020Q2 us-gaap Revenues
Revenues
33000 USD
CY2019Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
55000 USD
us-gaap Revenues
Revenues
0 USD
CY2020Q2 us-gaap Revenues
Revenues
33000 USD
CY2019Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
55000 USD
us-gaap Revenues
Revenues
0 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2763000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1881000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4669000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3336000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4147000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
714000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7478000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1397000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6910000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
2595000 USD
us-gaap Operating Expenses
OperatingExpenses
12147000 USD
us-gaap Operating Expenses
OperatingExpenses
4733000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6877000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2595000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12092000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4733000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
161000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
59000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
79000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
50000 USD
CY2020Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0 USD
CY2019Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
758000 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
651000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
98000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
190000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
59000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6779000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2569000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11902000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4674000 USD
CY2020Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1426000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6889000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2569000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5013000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4674000 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1508000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5353000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3327000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5664000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6182000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.59
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8292809 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1345402 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5243577 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1345402 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-59463000 USD
CY2020Q1 nlnk Preferred Stock Accretion Of Preferred Dividend Prior To Acquisition
PreferredStockAccretionOfPreferredDividendPriorToAcquisition
651000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
116949000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
64186000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
177000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
340000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
121538000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
274000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
116465000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-46919000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
48000 USD
CY2019Q1 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
750000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2105000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-49726000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40000 USD
CY2019Q2 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
758000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2569000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-53013000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-5013000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4674000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
451000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
88000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
313000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
-29000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
nlnk Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability
FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
93000 USD
nlnk Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability
FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
-4000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
426000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2416000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2423000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-85000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3237000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
103000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
4474000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16410000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4471000 USD
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
84179000 USD
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
0 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
14000 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
84165000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
16000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
67745000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4471000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4952000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14022000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72697000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9551000 USD
us-gaap Nature Of Operations
NatureOfOperations
Organization and Description of Business<div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lumos Pharma, Inc. ("Lumos" or the "Company") is a clinical-stage biopharmaceutical company focused on the identification, acquisition, in-license, development, and commercialization of novel products for the treatment of rare diseases. The Company's mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. The Company's principal offices are located in Austin, Texas. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lumos and its subsidiaries have historically devoted substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company believes that its existing cash and cash equivalents as of June 30, 2020 are sufficient to satisfy its operating cash and needs to support the Company through read out of the Phase 2b clinical trial for its LUM-201 product candidate and at least one year after the filing of the Quarterly Report on Form 10-Q in which these financial statements are included. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company’s plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position and may materially affect the Company’s ability to continue as a going concern. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In March 2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of Coronavirus, a global pandemic. In response to the COVID-19 pandemic, “shelter in place” orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our offices, clinical trial sites, key vendors, and partners. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The extent of the effect on the Company’s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic at this time, if the pandemic continues to evolve into a severe worldwide crisis, it could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. The financial statements do not reflect any adjustments as a result of the pandemic.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with NewLink Genetics Corporation</span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On March 18, 2020, Lumos, the company formerly known as NewLink Genetics Corporation ("NewLink"), completed a merger in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September 30, 2019, by and among the Company, Cyclone Merger Sub, Inc. ("Merger Sub"), and what was then known as Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”) (as amended, the "Merger Agreement"), pursuant to which Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of NewLink (the "Merger"). </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 18, 2020, and prior to the effective time of the Merger (the “Effective Time”), NewLink effected a 1-for-9 reverse stock split of its common stock (the “Reverse Stock Split”) and, following the Merger, changed its name to “Lumos Pharma, Inc.” Unless otherwise noted herein, all references to share amounts give effect to the Reverse Stock Split. Following the completion of the Merger, the business being conducted by the Company became primarily the business conducted by Private Lumos, which is a biopharmaceutical company focused on the identification, acquisition, in-license, development, and commercialization of novel products for the treatment of rare diseases. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Immediately following the Reverse Stock Split and the completion of the Merger, there were 8,292,803 shares of the Company’s common stock outstanding. Under the terms of the Merger, Private Lumos stockholders received an aggregate of 4,146,398 shares of our common stock, at an exchange rate of (i) 0.1308319305 shares of common stock in exchange for each share of Private Lumos common stock outstanding immediately prior to the Merger, (ii) 0.0873621142 shares of our common stock in exchange for each share of Private Lumos Series A Preferred Stock outstanding immediately prior to the Merger, and (iii) 0.1996348626 shares of our common stock in exchange for each share of Private Lumos Series B Preferred Stock outstanding immediately prior to the Merger. Immediately following the Merger, the former Private Lumos stockholders </span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">beneficially owned approximately 50% of the shares of the Company and the former NewLink stockholders beneficially owned approximately 50% of the shares of the Company. For accounting purposes, Private Lumos is considered to have acquired NewLink in the Merger. NewLink's shares of common stock listed on The Nasdaq Global Market, previously trading through the close of business on Wednesday, March 18, 2020 (the "Merger Date") under the ticker symbol "NLNK", commenced trading on The Nasdaq Global Market, under the ticker symbol "LUMO", on Thursday, March 19, 2020. The accompanying condensed consolidated financial statements and notes give retroactive effect to the exchange ratio and change in par value for all periods presented.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Merger was accounted for as a reverse merger with Private Lumos deemed the accounting acquiror for accounting purposes. Further, the Merger was accounted for as an asset acquisition rather than a business combination because the assets acquired and liabilities assumed from NewLink did not meet the definition of a business as defined by ASC 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Business Combinations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as NewLink did not contain the processes in place to generate outputs. </span></div><div style="text-indent:22pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As such, the results of operations and cash flows prior to the Merger Date, relate to Private Lumos. Subsequent to the Merger Date the information in these unaudited financial statements relates to the Company and its consolidated entities. All share and per share amounts in the financial statements and related notes have been retroactively adjusted, where applicable, for all periods presented to give effect to the exchange ratio applied in connection with the Merger and the Reverse Stock Split.</span></div>
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8292803 shares
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation <div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of presentation</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its subsidiaries and all intercompany amounts have been eliminated. The unaudited interim consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019, included in NewLink's Annual Report on Form 10-K and the Company's Current Report on Form 8-K/A, filed with the SEC on May 29, 2020. The financial results for any interim period are not necessarily indicative of financial results for the full year.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s historical results are not necessarily indicative of the results to be expected in the future and the Company’s operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.</span></div>The balance sheet at December 31, 2019 was derived from audited financial statements, but does not include all disclosure required by U.S. GAAP.
CY2020Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
426000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds.
CY2020Q2 nlnk Deferred Compensation Arrangement With Individual Exercise Price Range Lower Range Limit Percent
DeferredCompensationArrangementWithIndividualExercisePriceRangeLowerRangeLimitPercent
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
403000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
154000 USD
CY2020Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
426000 USD
CY2020Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
426000 USD
CY2020Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
7100000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
274000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
88000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
376000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
278000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
654000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17000 USD
CY2020Q2 nlnk Lessee Operating Lease Liability Unamortized Lease Incentive
LesseeOperatingLeaseLiabilityUnamortizedLeaseIncentive
182000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
819000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1400000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6900000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-4473000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1426000 USD
CY2019Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2416000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1426000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6889000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 nlnk Cares Act Operating Loss Carry Back Before Tax
CARESActOperatingLossCarryBackBeforeTax
4500000 USD
CY2020Q2 nlnk Cares Act Operating Loss Carry Back Before Tax
CARESActOperatingLossCarryBackBeforeTax
4500000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1400000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2400000 USD
CY2020Q2 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
9500000 USD
CY2020Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
653000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2569000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5013000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4674000 USD
CY2020Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0 USD
CY2019Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
758000 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
651000 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1508000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5353000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3327000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5664000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6182000 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8292809 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1345402 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5243577 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1345402 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.59
CY2019Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2019 us-gaap Restructuring Charges
RestructuringCharges
5600000 USD
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
4700000 USD
us-gaap Restructuring Charges
RestructuringCharges
0 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
3731000 USD
CY2020Q2 us-gaap Restructuring Reserve
RestructuringReserve
969000 USD
CY2020Q2 nlnk Cares Act Operating Loss Carry Back Before Tax
CARESActOperatingLossCarryBackBeforeTax
4500000 USD

Files In Submission

Name View Source Status
0001126234-20-000114-index-headers.html Edgar Link pending
0001126234-20-000114-index.html Edgar Link pending
0001126234-20-000114.txt Edgar Link pending
0001126234-20-000114-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image11.jpg Edgar Link pending
image211.jpg Edgar Link pending
image31.jpg Edgar Link pending
image71.jpg Edgar Link pending
lumo-2020630x10qxex101.htm Edgar Link pending
lumo-2020630x10qxex102.htm Edgar Link pending
lumo-2020630x10qxex311.htm Edgar Link pending
lumo-2020630x10qxex312.htm Edgar Link pending
lumo-2020630x10qxex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
nlnk-20200630.htm Edgar Link pending
nlnk-20200630.xsd Edgar Link pending
nlnk-20200630_cal.xml Edgar Link unprocessable
nlnk-20200630_def.xml Edgar Link unprocessable
nlnk-20200630_g1.jpg Edgar Link pending
nlnk-20200630_g2.jpg Edgar Link pending
nlnk-20200630_htm.xml Edgar Link completed
nlnk-20200630_lab.xml Edgar Link unprocessable
nlnk-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending